

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015, India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1 st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>
Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	Kind Attn.: Famroze Pochara Asst. Vice President
Date: June 5, 2017	
Re.: Press Release	

Dear Sir / Madam,


We enclose herewith a copy of press release dated June 5, 2017, titled Zydus receives final approval from the USFDA for Mirtazapine Orally Disintegrating Tablets USP.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, **Cadila Healthcare Limited**



Upen H. Shah
Company Secretary

Encl.: As above

Zydus receives final approval from the USFDA for Mirtazapine Orally Disintegrating Tablets USP

Ahmedabad, 5 June 2017

Zydus Cadila has received the final approval from the USFDA to market Mirtazapine Orally Disintegrating Tablets USP in strengths of 15 mg, 30 mg & 45 mg.

The drug is an anti-depressant and will be produced at the group's formulations manufacturing facility at Baddi.

The group now has more than 115 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
